

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 10, 2026

SkinHealth Systems Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39565
(Commission
File Number)

85-1908962
(IRS Employer
Identification No.)

3600 E. Burnett Street
Long Beach, CA
(Address of principal executive offices)

90815
(Zip Code)

(800) 603-4996
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value \$0.0001 per share	SKIN	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 10, 2026, SkinHealth Systems Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") in a virtual format. At the close of business on April 16, 2026, the record date for the Annual Meeting (the "Record Date"), there were 129,584,184 shares of the Company's Class A Common Stock, par value \$0.0001 per share ("Class A Common Stock") issued and outstanding, which constituted all of the issued and outstanding capital stock of the Company as of the Record Date. At the Annual Meeting, 93,406,914 of the Company's 129,584,184 outstanding shares of Class A Common Stock entitled to vote as of the Record Date, or approximately 72.08%, were present virtually or represented by proxy, and, therefore, a quorum was present.

The three proposals voted on at the Annual Meeting are more fully described in the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 24, 2026 (the "Proxy Statement").

The final voting results on the proposals presented for stockholder approval at the Annual Meeting are as follows:

Proposal No. 1: Election of Nine Directors

The Company's stockholders elected the nine directors listed below, each to serve for a term of one year, expiring at the Company's 2027 annual meeting of stockholders or until his or her successor is duly appointed or elected and qualified or until his or her earlier death, resignation, or removal from office, as follows:

Nominees	Votes For	Votes Withheld	Broker Non-Votes
Brenton L. Saunders	64,713,062	7,259,415	21,434,437
Pedro Malha	70,933,549	1,038,928	21,434,437
E. Scott Beattie	61,017,737	10,954,740	21,434,437
Stephen J. Fanning	68,732,826	3,239,651	21,434,437
Michelle Kerrick	70,684,772	1,287,705	21,434,437
Brian Miller	56,555,107	15,417,370	21,434,437
Doug Schillinger	61,107,166	10,865,311	21,434,437
Sachin Shridharani, M.D.	71,317,162	655,315	21,434,437
Kenneth Tripp	71,078,056	894,421	21,434,437

Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent, registered public accounting firm for the fiscal year ending December 31, 2026, as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes
93,125,701	235,673	45,540	0

Proposal No. 3: Advisory Vote on the Compensation of the Named Executive Officers

The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the Proxy Statement, as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes
58,604,735	12,346,541	1,021,201	21,434,437

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 16, 2026

SkinHealth Systems Inc.

By: /s/ Michael Monahan

Name: Michael Monahan

Title: Chief Financial Officer